Works matching AU Jiang, Yizhou

Results: 88
    1

    A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

    Published in:
    2017
    By:
    • Glisson, Bonnie;
    • Besse, Benjamin;
    • Dols, Manuel Cobo;
    • Dubey, Sarita;
    • Schupp, Marco;
    • Jain, Rajul;
    • Yizhou Jiang;
    • Menon, Hari;
    • Nackaerts, Kristiaan;
    • Orlov, Sergey;
    • Paz-Ares, Luis;
    • Ramlau, Rodryg;
    • Rui Tang;
    • Yilong Zhang;
    • Min Zhu;
    • Jiang, Yizhou;
    • Tang, Rui;
    • Zhang, Yilong;
    • Zhu, Min
    Publication type:
    journal article
    2

    Enhanced visual dominance in far space.

    Published in:
    Experimental Brain Research, 2015, v. 233, n. 10, p. 2833, doi. 10.1007/s00221-015-4353-2
    By:
    • Yue, Zhenzhu;
    • Jiang, Yizhou;
    • Li, You;
    • Wang, Pengfei;
    • Chen, Qi
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16

    Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S293, doi. 10.1016/j.clml.2018.07.238
    By:
    • Oluwole, Olalekan O.;
    • Bishop, Michael R.;
    • Gisselbrecht, Christian;
    • Gordon, Leo I.;
    • Kersten, Marie José;
    • Maloney, David G.;
    • Schmitz, Norbert;
    • Caballero, Maria Dolores;
    • Kuruvilla, John;
    • Song, Kevin W.;
    • Jacobson, Caron A.;
    • Nastoupil, Loretta J.;
    • Riedell, Peter;
    • Jiang, Yizhou;
    • Rossi, John M.;
    • Lee, Lillian;
    • Cheng, Paul;
    • Locke, Frederick L.
    Publication type:
    Article
    17

    Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S276, doi. 10.1016/j.clml.2018.07.203
    By:
    • Locke, Frederick L.;
    • Ghobadi, Armin;
    • Lekakis, Lazaros J.;
    • Miklos, David B.;
    • Jacobson, Caron A.;
    • Jacobsen, Eric;
    • Braunschweig, Ira;
    • Oluwole, Olalekan O.;
    • Siddiqi, Tanya;
    • Lin, Yi;
    • Reagan, Patrick M.;
    • Farooq, Umar;
    • Deol, Abhinav;
    • Bot, Adrian;
    • Rossi, John M.;
    • Jiang, Yizhou;
    • Xue, Allen;
    • Go, William Y.;
    • Neelapu, Sattva S.
    Publication type:
    Article
    18

    Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S277, doi. 10.1016/j.clml.2018.07.206
    By:
    • Locke, Frederick L.;
    • Ghobadi, Armin;
    • Jacobson, Caron A.;
    • Jacobsen, Eric;
    • Miklos, David B.;
    • Lekakis, Lazaros J.;
    • Braunschweig, Ira;
    • Oluwole, Olalekan O.;
    • Lin, Yi;
    • Siddiqi, Tanya;
    • Deol, Abhinav;
    • Reagan, Patrick M.;
    • Farooq, Umar;
    • Bot, Adrian;
    • Jiang, Yizhou;
    • Rossi, John M.;
    • Xue, Allen;
    • Go, William Y.;
    • Neelapu, Sattva S.
    Publication type:
    Article
    19

    KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S252, doi. 10.1016/j.clml.2017.07.013
    By:
    • Lee, Daniel W.;
    • Wayne, Alan;
    • Huynh, Van;
    • Handgretinger, Rupert;
    • Pieters, Rob;
    • Michel, Gerard;
    • Baruchel, Andre;
    • Feuchtinger, Tobias;
    • Bertrand, Yves;
    • Hemiston, Michelle;
    • Brown, Patrick;
    • Rossi, John;
    • Jiang, Yizhou;
    • Navale, Lynn;
    • Stout, Shanna;
    • Aycock, Jeff;
    • Mardiros, Armen;
    • Wiezorek, Jeff;
    • Jain, Rajul
    Publication type:
    Article
    20

    Axi-cel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S253, doi. 10.1016/j.clml.2017.07.014
    By:
    • Shah, Bijal;
    • Stock, Wendy;
    • Wierda, William;
    • Topp, Max;
    • Kersten, Marie José;
    • Houot, Roch;
    • Boissel, Nicolas;
    • Holmes, Houston;
    • Schiller, Gary;
    • Mardiros, Armen;
    • Rossi, John;
    • Jiang, Yizhou;
    • Shen, Tong;
    • Aycock, Jeff;
    • Stout, Shanna;
    • Wiezorek, Jeff;
    • Jain, Rajul
    Publication type:
    Article
    21

    Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S102, doi. 10.1016/j.clml.2016.07.148
    By:
    • Neelapu, Sattva;
    • Locke, Frederick;
    • Bartlett, Nancy;
    • Siddiqi, Tanya;
    • Chavez, Julio;
    • Hosing, Chitra;
    • Cashen, Amanda;
    • Budde, Lihua;
    • Bot, Adrian;
    • Rossi, John;
    • Navale, Lynn;
    • Jiang, Yizhou;
    • Aycock, Jeff;
    • Elias, Meg;
    • Wiezorek, Jeff;
    • Go, William
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50